Research Paper Volume 12, Issue 4 pp 3126—3139

LncRNA AK045171 protects the heart from cardiac hypertrophy by regulating the SP1/MG53 signalling pathway

Figure 2. AK045171 ameliorated the hypertrophy in vitro and in vivo induced by AngII and TAC treatment. (A, B) qPCR was used to evaluate the efficiency of AK045171overexpression adenovirus, which significantly elevated the level of AK045171 in cardiomyocytes and myocardium. (C) Echocardiographic parameters of the mice, including LVEDP, LVFS, LVEF, and LVESD, were evaluated with an ultrasound system. (C) Haematoxylin and eosin staining of the heart under TAC, TAC+Ad-AK045171 or TAC+ Ad-vector treatment. (D) Quantification of heart weight-to-tibial length ratio. (E) Immunostaining of α-SMA was used to evaluate the size of cardiomyocytes subjected to AngII, AngII+ Ad-AK045171 or AngII+Ad-vector treatment. (F) The level of the myocardial hypertrophy biomarkers ANP, BNP and β-MHC were detected using qPCR. * p<0.05 vs the Ang II+Ad-vector or TAC+Ad-vector group.